retatrutide safety retatrutide clinical trials profile A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity RETATRUTIDE: The “Next Big Fat

It's a fillip for new Novo Nordisk chief executive Mike Doustdar, who took the helm last year with a clear remit to defend the GLP-1-based weight loss and diabetes business from rivals like Eli Lilly, as well as knock-off versions of semaglutide that sidestep the company's intellectual property (IP).

California lawmakers are moving to cut Medicaid coverage for some expensive weight-loss drugs, such as Novo Nordisks Wegovy and Eli Lillys Zepbound, in a bid to reduce the states $12 billion budget deficit.

Colleen McCabe, PharmD, BCOP, and Lindsay Mundy, PharmD, BCOP, provided an engaging exploration of the benefits and potential pitfalls seen with the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in an oncology setting

This product is a compounded preparation and has not been approved by the FDA

p=0.046) was statistically significant but not clinically relevant

This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.